| # | Drug | Count |
|---|---|---|
| 0 | NIVOLUMAB | 135 |
| 1 | IPILIMUMAB | 75 |
| 2 | CARBOPLATIN | 62 |
| 3 | PACLITAXEL | 26 |
| 4 | PEMETREXED DISODIUM | 26 |
| 5 | PEMETREXED | 24 |
| 6 | CISPLATIN | 14 |
| 7 | DURVALUMAB | 14 |
| 8 | ESOMEPRAZOLE | 9 |
| 9 | ESOMEPRAZOLE MAGNESIUM | 9 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ZONGERTINIB | 1 | 0.0060 |
| 1 | NIVOLUMAB AND RELATLIMAB-RMBW | 1 | 0.0019 |
| 2 | XYLOMETAZOLINE HYDROCHLORIDE | 1 | 0.0018 |
| 3 | IPILIMUMAB | 75 | 0.0017 |
| 4 | NIVOLUMAB | 135 | 0.0014 |
| 5 | TREMELIMUMAB | 5 | 0.0011 |
| 6 | FOSNETUPITANT AND PALONOSETRON | 1 | 0.0008 |
| 7 | NETUPITANT AND PALONOSETRON | 1 | 0.0008 |
| 8 | WHITE PETROLATUM | 1 | 0.0007 |
| 9 | POTASSIUM IODIDE | 1 | 0.0007 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Lymphocyte Activation Gene-3 Blocker [EPC] | 1 | 0.0019 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 80 | 0.0017 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 136 | 0.0014 |
| 3 | Programmed Death Ligand-1 Blocker [EPC] | 14 | 0.0006 |
| 4 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 2 | 0.0003 |
| 5 | Platinum-based Drug [EPC] | 78 | 0.0003 |
| 6 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 2 | 0.0002 |
| 7 | Microtubule Inhibitor [EPC] | 32 | 0.0002 |
| 8 | Stimulant Laxative [EPC] | 2 | 0.0001 |
| 9 | Antimalarial [EPC] | 1 | 0.0001 |